title: YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome.
abstract: YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.
authors.affiliation: The Allogeneic Hematopoietic Cell Transplantation Laboratory, Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Kornblit
authors.affiliation: Division of Biostatistics, Institute for Health & Society, Medical College of Wisconsin, Milwaukee, WI, USA.|Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: T
authors.initials: T
authors.lastname: Wang
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.|Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Lee
authors.affiliation: Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA.
authors.forename: S R
authors.initials: SR
authors.lastname: Spellman
authors.affiliation: Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: X
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Institute for Experimental Cellular Therapy, Universitatsklinikum Essen KMT, Essen, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Fleischhauer
authors.affiliation: Zentrales Knochenmarkspender-Register Deutschland, Ulm, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Müller
authors.affiliation: Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Verneris
authors.affiliation: Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
authors.forename: K
authors.initials: K
authors.lastname: Müller
authors.affiliation: Department of Oncology and Medicine, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.|Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
authors.forename: J S
authors.initials: JS
authors.lastname: Johansen
authors.affiliation: The Allogeneic Hematopoietic Cell Transplantation Laboratory, Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
authors.forename: L
authors.initials: L
authors.lastname: Vindelov
authors.affiliation: Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.|Laboratory of Molecular Medicine, Department of Clinical Immunology - Section 7631, Rigshospitalet, Copenhagen, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Garred
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D064591:Allografts; D001782:Blood Donors; D000071451:Chitinase-3-Like Protein 1 / Q000097:blood*; D015331:Cohort Studies; D046148:Donor Selection / Q000379:methods*; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood*; D006133:Growth Substances / Q000097:blood; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D011379:Prognosis; D055815:Young Adult
chemical_list: C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D006133:Growth Substances